Anti-cancer drug benefits women with breast cancer who have failed previous treatments
In a late-breaking presentation to the 2013 European Cancer Congress (ECC2013) [1] today, Professor Hans Wildiers will say: "This study shows that even in heavily pre-treated women, 75% of whom had cancer that has spread to the internal organs, T-DM1 nearly doubles progression-free survival — the length of time before disease progression or death, whichever occurs first — compared to standard therapy, and with a more favourable safety profile. …